TABLE 1.
Items | TAO group (n = 28) | HCs (n = 22) | P-value |
Age (years) | 44.25 ± 12.71 | 44.27 ± 12.75 | 0.907a |
Gender (female/male) | 15/13 | 12/10 | 0.945b |
Disease duration (months) | 18.39 ± 20.90 | – | |
CAS | 2.54 ± 1.26 | – | |
Visual acuity | 0.81 ± 0.25 | 0.98 ± 0.18 | 0.009c |
QoL scores | |||
Visual functioning | 61.95 ± 26.77 | – | |
Appearance | 66.65 ± 19.70 | – | |
Total score of HARS | 15.39 ± 8.51 | 2.68 ± 2.61 | <0.001a |
Total score of HDRS | 15.25 ± 9.96 | 2.23 ± 1.93 | <0.001a |
Total score of MoCA | 26.75 ± 2.66 | 29.09 ± 1.02 | <0.001a |
Data were presented as mean ± standard deviation unless otherwise indicated.
CAS, clinical activity score; QoL, quality of life; HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton Depression Rating Scale; MoCA, Montreal Cognitive Assessment; TAO, thyroid-associated ophthalmopathy; HCs, healthy controls; n, number of subjects.
aP-value with Mann–Whitney test.
bP-value with Chi-square test.
cP-value with two-sample t-test.